Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20484561 | 0.95 | — | — | |
| SCHEMBL9851 | 0.95 | — | — | |
| SCHEMBL28238772 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL28816648 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL15200590 | 0.82 | — | — | |
| Formaldehyde SCHEMBL28219528 | 0.82 | — | — | |
| SCHEMBL1470750 | 0.82 | SLC6A4 (0.31) | — | |
| Hydrochloric Acid SCHEMBL19732657 | 0.82 | — | — | |
| SCHEMBL562817 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL27776273 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119164993-A | Analysis method for determining chloride ion content in 3, 3-difluoro-cyclobutane hydrochloride and application thereof | 南京药石科技股份有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-120192296-A | Amide derivative and preparation and application thereof | 顺毅股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| CN-113490664-B | TYK2 inhibitors and uses thereof | 阿鲁米斯公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119707925-A | Compounds as KIF18A inhibitors and uses thereof | 南京圣和药物研发有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119409710-A | Oxamide substituted hepatitis b virus tricyclic inhibitors | 圣拉斐尔医院有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119164993-A | Analysis method for determining chloride ion content in 3, 3-difluoro-cyclobutane hydrochloride and application thereof | 南京药石科技股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119164993-A | Analysis method for determining chloride ion content in 3, 3-difluoro-cyclobutane hydrochloride and application thereof | 南京药石科技股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-119164993-A | Analysis method for determining chloride ion content in 3, 3-difluoro-cyclobutane hydrochloride and application thereof | 南京药石科技股份有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-3293177-B1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2024-11-27 | — | — | EP | disclosed |
| CN-114555608-B | Oxamide substituted hepatitis b virus tricyclic inhibitors | 圣拉斐尔医院有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-110256440-B | Phthalazine isoxazole alkoxy derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-115151533-A | MEK inhibitors and therapeutic uses thereof | 医疗免疫工程公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113490664-A | TYK2 inhibitors and uses thereof | 埃斯克疗法股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-112028825-A | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| CN-107683279-B | Tyrosine kinase inhibitor and pharmaceutical composition containing same | 广东众生睿创生物科技有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-211705967-U | Extraction equipment for producing difluorocyclobutane amine hydrochloride | 李岩松 | 2020-10-20 | — | — | CN | disclosed |
| US-10654808-B2 | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190119217-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2019-04-25 | — | — | US | disclosed |
| CN-106046007-B | Tyrosine kinase inhibitor and pharmaceutical composition comprising the tyrosine kinase inhibitor | 广东众生睿创生物科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-3293177-A1 | TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-03-14 | — | — | EP | disclosed |